Jaume Capdevila, MD, Vall d'Hebron Hospital, discusses the final analysis of the phase 3 COMPETE trial (NCT03049189). Data ...

A panelist discusses how data from the DeLLphi-304 trial position tarlatamab as a potential new standard for relapsed ...

A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of ...

The investigational oral KRAS G12D inhibitor VS-7375 (GFH375) has shown a promising early safety profile and preliminary antitumor activity in pretreated patients with advanced solid tumors harboring ...

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

Chronic graft-versus-host disease (GVHD) is a cause of late morbidity and mortality after allogeneic stem cell transplant.

A recent trial reveals lenvatinib plus everolimus significantly improves progression-free survival in metastatic renal cell ...

Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of ...

At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns and the need for further research.

An exosome-based treatment of glioblastoma multiforme (GBM) has received orphan drug designation from the FDA. 1 Exousia AI, ...